RU2013102967A - Соединения, действующие на многочисленные рецепторы простагландина, дающие общую противовоспалительную реакцию - Google Patents
Соединения, действующие на многочисленные рецепторы простагландина, дающие общую противовоспалительную реакцию Download PDFInfo
- Publication number
- RU2013102967A RU2013102967A RU2013102967/04A RU2013102967A RU2013102967A RU 2013102967 A RU2013102967 A RU 2013102967A RU 2013102967/04 A RU2013102967/04 A RU 2013102967/04A RU 2013102967 A RU2013102967 A RU 2013102967A RU 2013102967 A RU2013102967 A RU 2013102967A
- Authority
- RU
- Russia
- Prior art keywords
- group
- alkyl
- compound according
- aryl
- alkoxy
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract 24
- 230000007234 antiinflammatory process Effects 0.000 title 1
- 125000000217 alkyl group Chemical group 0.000 claims abstract 24
- 125000003118 aryl group Chemical group 0.000 claims abstract 18
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract 15
- 125000003545 alkoxy group Chemical group 0.000 claims abstract 14
- 125000004104 aryloxy group Chemical group 0.000 claims abstract 12
- 229910052736 halogen Inorganic materials 0.000 claims abstract 12
- 150000002367 halogens Chemical class 0.000 claims abstract 12
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims abstract 12
- -1 nitro, amino Chemical group 0.000 claims abstract 12
- 125000004093 cyano group Chemical group *C#N 0.000 claims abstract 6
- 125000000753 cycloalkyl group Chemical group 0.000 claims abstract 2
- 229910052731 fluorine Inorganic materials 0.000 claims abstract 2
- 239000011737 fluorine Substances 0.000 claims abstract 2
- 125000003709 fluoroalkyl group Chemical group 0.000 claims abstract 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims abstract 2
- 229910052760 oxygen Inorganic materials 0.000 claims abstract 2
- 229910052717 sulfur Inorganic materials 0.000 claims abstract 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 2
- DCLCBDKYYKUMIP-UHFFFAOYSA-N 3-[1-[[2-(cyclopentylmethoxy)-5-(trifluoromethyl)phenyl]methyl]-5-methylpyrazol-3-yl]propanoic acid Chemical compound CC1=CC(CCC(O)=O)=NN1CC1=CC(C(F)(F)F)=CC=C1OCC1CCCC1 DCLCBDKYYKUMIP-UHFFFAOYSA-N 0.000 claims 1
- KVDYESNTWCANOH-UHFFFAOYSA-N 3-[1-[[5-bromo-2-(2-ethylbutoxy)phenyl]methyl]-5-methylpyrazol-3-yl]propanoic acid Chemical compound CCC(CC)COC1=CC=C(Br)C=C1CN1C(C)=CC(CCC(O)=O)=N1 KVDYESNTWCANOH-UHFFFAOYSA-N 0.000 claims 1
- MSILREZNZDUJJQ-UHFFFAOYSA-N 3-[1-[[5-bromo-2-(cyclopentylmethoxy)phenyl]methyl]-5-methylpyrazol-3-yl]propanoic acid Chemical compound CC1=CC(CCC(O)=O)=NN1CC1=CC(Br)=CC=C1OCC1CCCC1 MSILREZNZDUJJQ-UHFFFAOYSA-N 0.000 claims 1
- NTKCCANMCAOSKM-UHFFFAOYSA-N 3-[1-[[5-chloro-2-(2-ethylbutoxy)phenyl]methyl]-5-methylpyrazol-3-yl]propanoic acid Chemical compound CCC(CC)COC1=CC=C(Cl)C=C1CN1C(C)=CC(CCC(O)=O)=N1 NTKCCANMCAOSKM-UHFFFAOYSA-N 0.000 claims 1
- FWLNGQKMSQARPI-UHFFFAOYSA-N 3-[1-[[5-chloro-2-[(4-chlorophenyl)methoxy]phenyl]methyl]-5-methylpyrazol-3-yl]-n-(trifluoromethylsulfonyl)propanamide Chemical compound CC1=CC(CCC(=O)NS(=O)(=O)C(F)(F)F)=NN1CC1=CC(Cl)=CC=C1OCC1=CC=C(Cl)C=C1 FWLNGQKMSQARPI-UHFFFAOYSA-N 0.000 claims 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims 1
- 229910052794 bromium Inorganic materials 0.000 claims 1
- 125000004432 carbon atom Chemical group C* 0.000 claims 1
- 229910052801 chlorine Inorganic materials 0.000 claims 1
- 239000000460 chlorine Substances 0.000 claims 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 1
- UUEVFMOUBSLVJW-UHFFFAOYSA-N oxo-[[1-[2-[2-[2-[4-(oxoazaniumylmethylidene)pyridin-1-yl]ethoxy]ethoxy]ethyl]pyridin-4-ylidene]methyl]azanium;dibromide Chemical compound [Br-].[Br-].C1=CC(=C[NH+]=O)C=CN1CCOCCOCCN1C=CC(=C[NH+]=O)C=C1 UUEVFMOUBSLVJW-UHFFFAOYSA-N 0.000 claims 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 1
- 125000001153 fluoro group Chemical group F* 0.000 abstract 1
- 125000005843 halogen group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Diabetes (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Endocrinology (AREA)
- Rheumatology (AREA)
- Emergency Medicine (AREA)
- Reproductive Health (AREA)
- Transplantation (AREA)
- Pain & Pain Management (AREA)
- Child & Adolescent Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Tropical Medicine & Parasitology (AREA)
- Ophthalmology & Optometry (AREA)
- Heart & Thoracic Surgery (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US36075510P | 2010-07-01 | 2010-07-01 | |
| US61/360,755 | 2010-07-01 | ||
| PCT/US2011/042729 WO2012003414A1 (en) | 2010-07-01 | 2011-07-01 | Compounds act at multiple prostaglandin receptors giving a general anti-inflammatory response |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2013102967A true RU2013102967A (ru) | 2014-08-10 |
Family
ID=44514984
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2013102967/04A RU2013102967A (ru) | 2010-07-01 | 2011-07-01 | Соединения, действующие на многочисленные рецепторы простагландина, дающие общую противовоспалительную реакцию |
Country Status (18)
| Country | Link |
|---|---|
| US (3) | US8492424B2 (https=) |
| EP (1) | EP2588459B1 (https=) |
| JP (1) | JP5922116B2 (https=) |
| KR (1) | KR20130141434A (https=) |
| CN (1) | CN103038219B (https=) |
| AR (1) | AR082073A1 (https=) |
| AU (1) | AU2011272716B2 (https=) |
| BR (1) | BR112013000065A2 (https=) |
| CA (1) | CA2804194C (https=) |
| CL (1) | CL2013000002A1 (https=) |
| CO (1) | CO6680625A2 (https=) |
| ES (1) | ES2625355T3 (https=) |
| MX (1) | MX2013000170A (https=) |
| PH (1) | PH12013500121A1 (https=) |
| RU (1) | RU2013102967A (https=) |
| SG (1) | SG186886A1 (https=) |
| TW (1) | TW201206891A (https=) |
| WO (1) | WO2012003414A1 (https=) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10206813B2 (en) | 2009-05-18 | 2019-02-19 | Dose Medical Corporation | Implants with controlled drug delivery features and methods of using same |
| US12478503B2 (en) | 2009-05-18 | 2025-11-25 | Glaukos Corporation | Implants with controlled drug delivery features and methods of using same |
| US8859606B2 (en) * | 2010-07-01 | 2014-10-14 | Allergan, Inc. | Compounds act at multiple prostaglandin receptors giving a general anti-inflammatory response |
| US9006450B2 (en) | 2010-07-01 | 2015-04-14 | Boehringer Ingelheim International Gmbh | Compounds, pharmaceutical compositions and uses thereof |
| AU2012358983B2 (en) * | 2011-12-21 | 2017-09-14 | Allergan, Inc. | Compounds acting at multiple prostaglandin receptors giving a general anti-inflammatory response |
| US9035071B2 (en) * | 2011-12-27 | 2015-05-19 | Allergan, Inc. | Compounds acting at multiple prostaglandin receptors giving a general anti-inflammatory response |
| CA2862266C (en) | 2011-12-27 | 2016-10-04 | Allergan, Inc. | Compounds acting at multiple prostaglandin receptors giving a general anti-inflammatory response |
| WO2014028762A1 (en) | 2012-08-15 | 2014-02-20 | University Of Virginia Patent Foundation | Compositions and methods for treating peripheral arterial disease |
| CA2898720A1 (en) * | 2013-01-21 | 2014-07-24 | Allergan, Inc. | Compounds act at multiple prostaglandin receptors giving a general anti-inflammatory response |
| US9387196B2 (en) | 2013-10-31 | 2016-07-12 | Allergan, Inc. | 3-{1-[5-chloro-2-(2-ethylbutoxy)benzyl]-5-methyl-1H-pyrazol-3-yl}propanoic acid in crystalline form and methods for use thereof |
| CN106146400A (zh) * | 2015-03-20 | 2016-11-23 | 四川大学 | 苄基-1h-吡唑、苄基-1h-吡咯衍生物及其制备方法和用途 |
| US10462745B2 (en) | 2016-01-15 | 2019-10-29 | Google Llc | Systems and methods for extending battery life by monitoring device activity |
| CN107723304A (zh) * | 2016-08-10 | 2018-02-23 | 中国科学院上海生命科学研究院 | Prkar2a在炎症消退中的应用 |
| WO2020113094A1 (en) | 2018-11-30 | 2020-06-04 | Nuvation Bio Inc. | Pyrrole and pyrazole compounds and methods of use thereof |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4166452A (en) | 1976-05-03 | 1979-09-04 | Generales Constantine D J Jr | Apparatus for testing human responses to stimuli |
| US4256108A (en) | 1977-04-07 | 1981-03-17 | Alza Corporation | Microporous-semipermeable laminated osmotic system |
| US4265874A (en) | 1980-04-25 | 1981-05-05 | Alza Corporation | Method of delivering drug with aid of effervescent activity generated in environment of use |
| US4826868A (en) * | 1986-05-29 | 1989-05-02 | Ortho Pharmaceutical Corporation | 1,5-Diaryl-3-substituted pyrazoles pharmaceutical compositions and use |
| US7273883B2 (en) | 2000-09-14 | 2007-09-25 | Allergan, Inc. | Prostaglandin EP4 antagonist |
| US7217725B2 (en) | 2000-09-14 | 2007-05-15 | Allergan, Inc. | Prostaglandin D2 antagonist |
| US6511999B2 (en) | 2000-09-14 | 2003-01-28 | Allergan, Inc. | Interheteroaryl 7-oxabicyclic [2.2.1]heptane oxazoles as prostaglandin F2α antagonists |
| AU2004240705A1 (en) * | 2003-05-20 | 2004-12-02 | Merck Frosst Canada & Co. | Fluoro-methanesulfonyl-substituted cycloalkanoindoles and their use as prostaglandin D2 antagonists |
| ES2298832T3 (es) * | 2003-10-24 | 2008-05-16 | Glaxo Group Limited | Compuestos heterociclicos. |
| GB0508472D0 (en) | 2005-04-26 | 2005-06-01 | Glaxo Group Ltd | Compounds |
-
2011
- 2011-06-28 US US13/170,467 patent/US8492424B2/en active Active
- 2011-07-01 EP EP11734222.0A patent/EP2588459B1/en active Active
- 2011-07-01 JP JP2013518748A patent/JP5922116B2/ja not_active Expired - Fee Related
- 2011-07-01 KR KR1020137002639A patent/KR20130141434A/ko not_active Withdrawn
- 2011-07-01 PH PH1/2013/500121A patent/PH12013500121A1/en unknown
- 2011-07-01 MX MX2013000170A patent/MX2013000170A/es active IP Right Grant
- 2011-07-01 SG SG2013000054A patent/SG186886A1/en unknown
- 2011-07-01 AR ARP110102369A patent/AR082073A1/es unknown
- 2011-07-01 TW TW100123408A patent/TW201206891A/zh unknown
- 2011-07-01 RU RU2013102967/04A patent/RU2013102967A/ru not_active Application Discontinuation
- 2011-07-01 WO PCT/US2011/042729 patent/WO2012003414A1/en not_active Ceased
- 2011-07-01 US US13/808,020 patent/US20140121258A1/en not_active Abandoned
- 2011-07-01 CA CA2804194A patent/CA2804194C/en active Active
- 2011-07-01 AU AU2011272716A patent/AU2011272716B2/en not_active Ceased
- 2011-07-01 BR BR112013000065A patent/BR112013000065A2/pt not_active IP Right Cessation
- 2011-07-01 ES ES11734222.0T patent/ES2625355T3/es active Active
- 2011-07-01 CN CN201180038338.0A patent/CN103038219B/zh not_active Expired - Fee Related
-
2013
- 2013-01-02 CL CL2013000002A patent/CL2013000002A1/es unknown
- 2013-01-29 CO CO13016511A patent/CO6680625A2/es unknown
- 2013-05-20 US US13/898,254 patent/US20130253028A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US8492424B2 (en) | 2013-07-23 |
| US20120165382A1 (en) | 2012-06-28 |
| AU2011272716B2 (en) | 2016-05-19 |
| CA2804194A1 (en) | 2012-01-05 |
| CN103038219A (zh) | 2013-04-10 |
| US20130253028A1 (en) | 2013-09-26 |
| CA2804194C (en) | 2019-03-05 |
| CL2013000002A1 (es) | 2013-05-31 |
| WO2012003414A1 (en) | 2012-01-05 |
| SG186886A1 (en) | 2013-02-28 |
| AU2011272716A1 (en) | 2013-02-07 |
| PH12013500121A1 (en) | 2013-03-11 |
| EP2588459A1 (en) | 2013-05-08 |
| KR20130141434A (ko) | 2013-12-26 |
| JP2013535424A (ja) | 2013-09-12 |
| EP2588459B1 (en) | 2017-03-01 |
| ES2625355T3 (es) | 2017-07-19 |
| CO6680625A2 (es) | 2013-05-31 |
| TW201206891A (en) | 2012-02-16 |
| MX2013000170A (es) | 2013-05-28 |
| US20140121258A1 (en) | 2014-05-01 |
| BR112013000065A2 (pt) | 2019-09-24 |
| AR082073A1 (es) | 2012-11-07 |
| JP5922116B2 (ja) | 2016-05-24 |
| CN103038219B (zh) | 2016-08-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2013102967A (ru) | Соединения, действующие на многочисленные рецепторы простагландина, дающие общую противовоспалительную реакцию | |
| MA31759B1 (fr) | Compose amide | |
| PE20140826A1 (es) | Compuestos sustituidos fungicidas de 2-[2-halogenalquil-4-(fenoxi)-fenil]-1-[1,2,4]triazol-1-il-etanol | |
| RU2014117188A (ru) | Способ получения производных 4,4-дифтор-3,4-дигидроизохинолина | |
| AR063449A1 (es) | Proceso quimico para derivados de quinazolina, intermediarios | |
| RU2010141941A (ru) | Способ получения фторсодержащего производного ацилуксусной кислоты, способ получения фторсодержащего производного сложного эфира пиразолкарбоновой кислоты и способ получения фторсодержащего пиразолкарбоновой кислоты | |
| CY1110800T1 (el) | Μεθανοσουλφονικα αλατα αβιρατερονης-3-εστερων και ανακτηση αλατων αβιρατερονης-3-εστερων απο διαλυμα σε μεθυλο τριτ-βουτυλαιθερα | |
| AR071385A1 (es) | Compuestos de 2-imino-3-metil pirrolopirimidinona sustituida con tiofenilo,composiciones farmaceuticas que los contienen,y uso de los mismos para el tratamiento de patologias asociadas con la proteina beta amiloide,tales como alzheimer y otros formas de demencia. | |
| NO20081685L (no) | Fremgangsmate for fremstilling oksazolidin-beskyttelse aminodolforbindelser anvendbare som mellomprodukter for Florfenicol | |
| EA200802380A1 (ru) | Совместные кристаллы пирролидинонов | |
| MA38218A1 (fr) | Pyridine-2-amides utiles comme agonistes de cb2 | |
| EA200901051A1 (ru) | Новый способ разделения энантиомеров (3,4-диметоксибицикло[4.2.0]окта-1,3,5-триен-7-ил)нитрила и применение при синтезе ивабрадина | |
| RU2012105122A (ru) | Способ получения хиральных производных 3-триазолилсульфоксида | |
| AR064241A1 (es) | Metodos para el tratamiento de la depresion | |
| EA200800372A1 (ru) | Соединения и их соли, специфичные к ppar рецепторам и egf рецепторам, и их применение в области медицины | |
| RU2014129937A (ru) | Способы и промежуточные соединения для получения фармацевтических агентов | |
| ES2597853T3 (es) | Procedimiento para la preparación de ésteres alquílicos de ácido dihaloacetoacético | |
| RU2019122609A (ru) | Новые производные пиколиновой кислоты и их применение в качестве промежуточных соединений | |
| NI200700227A (es) | Procesos para la purificación de compuestos benzoxazol sustituidos. | |
| MX2014003636A (es) | Derivados de etinilo como moduladores del receptor glutamato metabotropico. | |
| EA201500483A1 (ru) | Усовершенствованные способы получения 1-арил-5-алкилпиразоловых соединений | |
| ATE552376T1 (de) | Blaue anthrachinonfarbstoffe, deren herstellung und verwendung | |
| RU2011120822A (ru) | Способ получения замещенных фенилаланинов | |
| DK2265580T3 (da) | Hidtil ukendt fremgangsmåde til fremstillingen af sulfonylpyrroler som HDAC-inhibitorer | |
| CY1108075T1 (el) | Διαδικασια για την παρασκευη αλκοξυκαρβονυλμεθοξυ-κυκλοπεντανιων |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20160316 |